Unlike withaferin A and FiVe1 (Bargagna-Mohan et al., 2007; Bollong et al., 2017), which are known vimentin inhibitors that degrade vimentin, our vimentin-binding compound R491 does not reduce the quantity of vimentin protein nor inhibit cancer cell growth (Figure 2), but instead alters the physical property of vimentin filaments (unpublished data) and compromises the mobility of cancer cells. The gene discussed is VIM; the disease is cancer.